Prurigo

ORLANDO — Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the American Academy of Dermatology Annual Meeting.

Patients with chronic prurigo experience high levels of perceived stress, stigmatization and body dysmorphia which are driven by both demographic and disease factors, according to a study.

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo nodularis in the European Union, Galderma announced in a press release.

The FDA has approved Nemluvio, in conjunction with topical corticosteroids and/or calcineurin inhibitors, for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older, Galderma announced in a press release.

Nemolizumab monotherapy improved the signs and symptoms of prurigo nodularis, according to new data published in JAMA Dermatology.

New interim, long-term results showed that nemolizumab improved signs and symptoms of atopic dermatitis including sleep, itch and quality of life, according to a presentation at the European Academy of Dermatology and Venereology Congress.

For patients using nemolizumab to treat prurigo nodularis, withdrawing medication led to a greater risk for relapse, according to a study presented at the European Academy of Dermatology and Venereology meeting.

The FDA approved Nemluvio in the form of a prefilled pen for subcutaneous injection for the treatment of prurigo nodularis in adults, Galderma announced in a press release.

Nemolizumab doses of 30 mg and 60 mg with topical corticosteroid treatment yielded positive results in adolescent patients with prurigo nodularis, according to a study.

Dupilumab showed continuous efficacy and safety in the long-term treatment of atopic dermatitis, according to a study.